{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:43:33Z","timestamp":1788176613456,"version":"build-2803163510"},"reference-count":33,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FDN\u2010154333"],"award-info":[{"award-number":["FDN\u2010154333"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004411","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","award":["G\u201014\u20100005977"],"award-info":[{"award-number":["G\u201014\u20100005977"]}],"id":[{"id":"10.13039\/100004411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Renin\u2010angiotensin\u2010aldosterone system inhibitors (RAASIs) are recommended for most patients with coronary artery disease (CAD). However, there is debate across guidelines as to which patients with CAD benefit the most from these agents. This study investigated the association between RAASIs and cardiovascular outcomes and acute kidney injury in a contemporary cohort of patients with CAD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients \u226565\u00a0years of age with CAD alive on April 1, 2012 in Ontario, Canada were included. Outcomes included major adverse cardiovascular events (MACE: cardiovascular death, myocardial infarction (MI), unstable angina, stroke, or coronary revascularization), and acute kidney injury (AKI) hospitalizations at 4\u00a0years. Inverse probability of treatment\u2010weighted Cox proportional hazards regression models was used to compare the rates of each outcome in patients treated with and without RAASIs (angiotensin\u2010converting enzyme inhibitors or angiotensin II receptor blockers).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 165,058 patients with CAD identified (mean age 75\u00a0years, 65.5% male, 64.7% prescribed RAASIs). After inverse\u2010probability weighting, treatment with RAASIs was associated with a lower rate of MACE compared with treatment without RAASIs (17.6% vs 18.2%, hazard ratio [HR]: 0.96, 95% CI: 0.93\u20130.99, respectively). However, treatment with RAASIs was associated with a higher rate of AKI compared with treatment without RAASIs (1.7% vs 1.5%, HR: 1.14, 95% CI: 1.02\u20131.29, respectively). The reduction in MACE was greater in patients with prior MI (HR: 0.87, 95% CI: 0.82\u20130.92) compared with patients without prior MI (HR: 1.00, 95% CI: 0.97\u20131.04, interaction <jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.01). The increase in AKI was lower in patients with prior MI (HR: 0.82, 95% CI: 0.66\u20131.00) compared with patients without prior MI (HR: 1.37, 95% CI: 1.19\u20131.57, interaction <jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study supports the continued use of RAASIs in patients with CAD, although the benefit appears smaller in magnitude than observed in prior trials. High\u2010risk patients, particularly those with prior MI, appear to benefit the most from RAASIs.<\/jats:p><\/jats:sec>","DOI":"10.1002\/phar.2624","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T14:30:52Z","timestamp":1631111452000},"page":"988-997","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Renin\u2010angiotensin\u2010aldosterone system inhibitors and major cardiovascular events and acute kidney injury in patients with coronary artery disease"],"prefix":"10.1002","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1936-5133","authenticated-orcid":false,"given":"Maneesh","family":"Sud","sequence":"first","affiliation":[{"name":"Schulich Heart Program Sunnybrook Health Sciences Centre University of Toronto Toronto ON Canada"},{"name":"Institute of Health Policy Management, and Evaluation University of Toronto Toronto ON Canada"},{"name":"ICES Toronto ON Canada"},{"name":"Temerty Faculty of Medicine University of Toronto Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis T.","family":"Ko","sequence":"additional","affiliation":[{"name":"Schulich Heart Program Sunnybrook Health Sciences Centre University of Toronto Toronto ON Canada"},{"name":"Institute of Health Policy Management, and Evaluation University of Toronto Toronto ON Canada"},{"name":"ICES Toronto ON Canada"},{"name":"Temerty Faculty of Medicine University of Toronto Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Chong","sequence":"additional","affiliation":[{"name":"ICES Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Koh","sequence":"additional","affiliation":[{"name":"ICES Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paymon M.","family":"Azizi","sequence":"additional","affiliation":[{"name":"Institute of Health Policy Management, and Evaluation University of Toronto Toronto ON Canada"},{"name":"ICES Toronto ON Canada"},{"name":"Temerty Faculty of Medicine University of Toronto Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Austin","sequence":"additional","affiliation":[{"name":"Institute of Health Policy Management, and Evaluation University of Toronto Toronto ON Canada"},{"name":"ICES Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9r\u00e8se A.","family":"Stukel","sequence":"additional","affiliation":[{"name":"Institute of Health Policy Management, and Evaluation University of Toronto Toronto ON Canada"},{"name":"ICES Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5274-7251","authenticated-orcid":false,"given":"Cynthia A.","family":"Jackevicius","sequence":"additional","affiliation":[{"name":"Institute of Health Policy Management, and Evaluation University of Toronto Toronto ON Canada"},{"name":"ICES Toronto ON Canada"},{"name":"Western University of Health Services Pomona California USA"},{"name":"VA Greater Los Angeles Healthcare System Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,9,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2014.05.013"},{"key":"e_1_2_7_3_1","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2012.07.013","article-title":"2012 ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons","volume":"24","author":"Fihn SD","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz425"},{"key":"e_1_2_7_5_1","first-page":"145","article-title":"Effects of an angiotensin\u2010converting\u2010enzyme inhibitor, ramipril, on cardiovascular events in high\u2010risk patients","volume":"3","author":"Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","journal-title":"N Engl J Med"},{"key":"e_1_2_7_6_1","first-page":"782","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double\u2010blind, placebo\u2010controlled, multicentre trial (the EUROPA study)","volume":"9386","author":"Fox KM","year":"2003","journal-title":"Lancet"},{"key":"e_1_2_7_7_1","first-page":"1174","article-title":"Effects of the angiotensin\u2010receptor blocker telmisartan on cardiovascular events in high\u2010risk patients intolerant to angiotensin\u2010converting enzyme inhibitors: a randomised controlled trial","volume":"9644","author":"Telmisartan Randomised AssessmeNt Study in ACEiswcDI","year":"2008","journal-title":"Lancet"},{"key":"e_1_2_7_8_1","first-page":"2058","article-title":"Angiotensin\u2010converting\u2010enzyme inhibition in stable coronary artery disease","volume":"20","author":"Braunwald E","year":"2004","journal-title":"N Engl J Med"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.685073"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu078"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2013-304348"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.07.783"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012690"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.114.001416"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-001821"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2003.10.004"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn164"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6607"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5705"},{"key":"e_1_2_7_22_1","first-page":"1547","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"15","author":"Investigators O","year":"2008","journal-title":"N Engl J Med"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-8-200104170-00007"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40697-015-0044-y"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2009.12.034"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2051"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069998"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1159\/000479338"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.7326\/0000605-200912150-00162"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2019-001010"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.12060"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j791"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14141"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.003956"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2624","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2624","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2624","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:48:14Z","timestamp":1761043694000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,22]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1002\/phar.2624"],"URL":"https:\/\/doi.org\/10.1002\/phar.2624","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,22]]},"assertion":[{"value":"2021-05-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}